Professor Meg Jardine is Director of the University of Sydney NHMRC Clinical Trials Centre, a group of more than 250 staff, and a practising clinician at Concord Repatriation Hospital. She has been influential in expanding the awareness and use of innovative and cost-effective methodologies to increase the generation of high-quality evidence. Her research focuses on investigating the progression and complications of non-communicable diseases through randomised trials and epidemiological analyses particularly kidney disease and diabetes, through randomised trials and epidemiological analyses. She has experience in the design and conduct of national and international trials and has authored >240 publications with > 15,000 citations. CI Jardine influences trial, guideline and practice policy through key international kidney disease networks. She is a current Executive Committee member of the International Society of Nephrology (ISN) and ISN-ACT Immediate Past Chair (2022-2024). She is the Chair of the American Society of Nephrology (ASN) Late Breaking Clinical Trials Decisionmakers (2024-2026). She serves as a Board Member of the Kidney Health Initiative, a public-private collaboration of the ASN and the US FDA. She is a member of the Australia and New Zealand Society of Nephrology (ANZSN) Research Advisory Committee. She has served as Executive Committee member of the Kidney Disease Improving Global Outcomes (KDIGO) international nephrology guidelines body (2020-2023), Board member of Australian Clinical Trials Alliance (ACTA) (2021-2023) and Deputy Chair of the Scientific Committee of the Australasian Kidney Trials Network (AKTN) (2015-20). CI Jardine is the proud recipient of the 2020 Australian and New Zealand Society of Nephrology T.J.Neale award for Outstanding Contribution to Nephrological Science.

Richard MacIsaac is a clinician-researcher who is currently Professor and Director of Endocrinology and Diabetes at St Vincent’s Hospital Melbourne and the University of Melbourne, Victoria, Australia. He is also the diabetes kidney disease co-stream leader for the Australian Centre for Accelerating Diabetes Innovations (ACADI), University of Melbourne. He has been a principal investigator for numerous diabetes clinical trials related to cardiovascular and kidney outcomes, including the landmark LEADER, SUSTAIN 6, CANVAS R, SCORED, FIGARO, FIDELIO and FLOW studies. His main research interest is diabetes and its acute and chronic complications, especially those related to cardiovascular and kidney disease. He has published over 300 research articles. His current specific research interests include the application of new therapies and technologies to improve the lives of people with diabetes, inpatient glycaemic control, defining the albuminuria and glomerular filtration rate relationship in diabetes, investigating new biomarkers for kidney and vascular disease in diabetes, and studying kidney function in Australian Aboriginal and Torres Strait Islander people. His contribution to the field of Diabetic Kidney Disease was acknowledged in 2025 when he as recognised at a Fellow of the International Society of Nephrology.